Cardiovascular devices
This article was originally published in Start Up
Executive Summary
Two areas of heart disease in want of therapeutic solutions are attracting device innovation: atrial fibrillation and congestive heart failure. Successful developers will be rewarded by large markets with little in terms of current competition.
You may also be interested in...
AHA Wrap-Up: Studies Emphasize Improved Outcomes, Cost Effectiveness
Cardiovascular investigators are now asking new questions, including how can treatment be targeted to those most likely to benefit, and when does aggressive treatment become too much? At the 2006 American Heart Association (AHA) meeting, these questions were at the top of everyone's list, and several highly anticipated studies attempted to provide some answers.
Deal Statistics Quarterly, Q2 2005
In this issue, we present another installment of our quarterly review of dealmaking-for April-June 2005. Our data comes from Windhover's Strategic Intelligence Systems, which covers deal activity within the pharmaceutical/biotechnology, medical device, and in vitro diagnostics industries.
Cardiovasc
Cardiovasc has a technology for growing functional endothelial cells in places where they normally do not grow. The company's two-part platform is built on a surface activation process that covalently bonds agents to materials, and a synthetic peptide, P-15, that attracts and anchors endothelial cells. The company's initial product will be a catheter-delivered stent, coated with the peptide, designed to encourage complete endothelialization and renew the interiors of aged and failing saphenous vein coronary bypass grafts.